Evotec and Sanofi to develop novel drug candidates from academic research

Within 3 years various candidates are to be developed for Sanofi

05-Oct-2018 - Evotec AG announced that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas. The BRIDGE LAB031 collaboration enables Evotec to access resources to enter research ...

Evotec and Celgene enter into strategic oncology partnership

22-May-2018 - Evotec AG announced that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology. Evotec has built one of the industry's broadest and most innovative pre-clinical discovery and development ...

Pierre Fabre and Roche extend collaboration agreement on companion diagnostic development

22-May-2018 - Pierre Fabre announced today the extension of a collaboration agreement with Roche on companion diagnostic development for W0101, Pierre Fabre's new antibody drug conjugate (ADC) product candidate targeting Insulin-like Growth Factor 1 (IGF-1) receptor currently in the international Phase I/II ...

Crescendo Biologics first major milestone in collaboration with Takeda reached

18-Apr-2018 - Crescendo Biologics Ltd, the developer of multifunctional biologics, including targeted T-cell engagers, announced that it has achieved the first major technical milestone under the terms of its collaboration with Takeda Pharmaceutical Company Limited. The global, strategic, multi-target ...

PhoreMost and Plexxikon collaborate to identify novel drug targets

16-Apr-2018 - PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo. Under the agreement, PhoreMost will apply its ...

Alnylam and Sanofi enter into strategic restructuring

Optimizing development and commercialization of RNAi therapeutics for rare diseases

09-Jan-2018 - Alnylam Pharmaceuticals, Inc. and Sanofi announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases. Specifically, Alnylam will obtain global development and ...

Confo Therapeutics enters into drug discovery collaboration with Roche

21-Dec-2017 - Confo Therapeutics, announced that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and ...

Heptares enters a research and drug discovery collaboration with Juntendo University

04-Sep-2017 - Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, announces the launch of a new research collaboration under its ORBIT initiative with Juntendo University in Tokyo, Japan. The new collaboration, Heptares’ fourth ORBIT programme, is with the research group of Professor ...

Exscientia enters strategic drug discovery collaboration with GSK

Pre-clinical collaboration focused on up to 10 targets

03-Jul-2017 - Exscientia, a company for Artificial Intelligence (AI)-driven drug discovery, announces it has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). During this collaboration, Exscientia will apply its AI enabled platform and combine this with the expertise of GSK, in ...

Heptares enters a Research and Drug Discovery Collaboration with New York University

New programme focused on key GPCR target implicated in aggressive brain cancer

28-Jun-2017 - Heptares Therapeutics announces the launch of a new research collaboration under its ORBIT initiative with New York University (NYU) School of Medicine. This new collaboration will support a multi-year programme with NYU’s drug discovery accelerator group, the Office of Therapeutics Alliances ...